Dailipharma
ActiveSummary
The computed 12-month bankruptcy probability of Dailipharma is 1.8% (moderate). The 2025 annual accounts show equity of €74,467 and a net result of €3,297. Equity is growing by about 16% per year across the filed financial years. Its solvency ranks better than 40% of 22,195 sector peers (NACE 47, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.